



VALIDATED STABILITY INDICATING HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD FOR THE QUANTIFICATION OF ASENAPINE MALEATE 
Original Article 
 
G. LAKSHMI KALPANA1*, G. DEVALARAO3, M. BHAGAVAN RAJU3, T. PRAVEENKUMAR4 
1Research Scholar, Jawaharlal Nehru Technological University, Hyderabad, 2Principal, KVSR Siddhartha College of Pharmaceutical 
Sciences, Vijayawada, 3Principal, Gland Institute of Pharmaceutical Sciences, Hyderabad, 4
 Received: 15 Jul 2015 Revised and Accepted: 10 Sep 2015 
Formulation R and D, Ricon pharma India 
private limited, Hyderabad 
Email: kalpanaghanta@gmail.com       
ABSTRACT 
Objective: A stability indicating high performance liquid chromatography method using the photodiode array 
Methods: The method utilized a BDS Y Persil C18 (250 x 4.6 mm, 5 µm) column with 0.1% orthophosphoric acid and methanol (65:35 v/v) as 
mobile phase. The analysis was performed at 30 
detector is developed and validated 
for the analysis of asenapine in bulk and in its tablet formulation. 
o
Results: Under optimized experimental conditions, asenapine was eluted from the column at a retention time of 6.781 min. The method was linear 
in the range of 100-300 µg/ml. The linear regression data showed good relationship (correlation coefficient (R
C column temperature with a flow rate of 1 ml/min and detection at 227 nm. The method was 
validated for specificity, sensitivity, precision, linearity, accuracy and robustness. Asenapine was subjected to stress degradation studies under 
acidic, basic, oxidative, thermal and photolytic conditions. 
2
Conclusion: The proposed stability indicting high performance liquid chromatography method is sensitive, precise, accurate, robust and specific. 
This method can be used for quantification of asenapine in bulk drug and in tablet dosage form in the presence of its stress degradation products. 
) = 0.9999). The relative standard 
deviation and mean recovery values were within limits. The analytical performance of the method was not affected when small variations in the 
experimental parameters were made. Degradation products resulting from stress degradation studies did not interfere with the detection of 
asenapine. 
Keywords: Antipsychotic drug, Stress degradation, High performance liquid chromatography, Quantification. 
 
INTRODUCTION 
Asenapine [1-3], chemically known as (3aRS,12bRS)-rel-5-Chloro-
2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-
c]pyrrole, is a second generation atypical antipsychotic agent. 
Asepanine is approved by Food and Drug Administration
Few reports are found in the literature for asenapine determination 
in pharmaceutical formulations [4-10], human plasma [11], human 
urine [12] and postmortem [13] samples. These include Ultra Violet 
(UV) spectrophotometry [4, 5], visible spectrophotometry [6], high 
performance liquid chromatography [7-10], 
 in 2009. 
Asenapine is long-term effective in the treatment of schizophrenia, 
potential to reduce the incidence of relapse, acute manic/mixed 
states related to bipolar I disorder.  
liquid chromatography-
mass spectrometry [11, 12] and gas chromatography-mass 
spectrometry 
The reported stability indicating methods suffers from disadvantages 
such as narrow range of linearity, preparation of buffer solutions, use 
of triple solvent system as mobile phase, less correlation coefficient 
value, lack of accuracy and sensitivity. Furthermore one of the three 
methods [15] is applied only to rat plasma sample.  
[13]. None of the above reported methods is stability 
indicating. To the best of our knowledge three stability indicating 
high performance liquid chromatographic methods [14-16] are 
found in the literature for the quantification of asenapine in the 
presence of its degradation products.  
Hence, the present investigation is aimed to develop and validate a 
simple, sensitive and accurate stability indicating high performance 
liquid chromatography method for the quantification of the 
asenapine in bulk and in its tablet formulation. The proposed have 
the advantages of broad linearity (upto 300 μg/ml), do not involve 
preparation of buffer, use of double solvent system as mobile phase 
and high correlation coefficient value (0.9999). The injection volume 
(10 μl) is less than the reported methods.  
MATERIALS AND METHODS 
Apparatus and HPLC conditions 
A Waters 2695 alliance with binary high performance liquid 
chromatography (HPLC) pump equipped with the Waters 2998 
photodiode array (PDA) detector and Waters Empower2 software 
were used in the present investigation. BDS Y Persil C18 (250 x 4.6 
mm; 5 µm particle size) analytical column was used for separation 
and analysis of the asenapine. The column temperature was 
maintained at 30±1 o
Mobile phase 
C. The separation was done under isocratic 
elution with flow rate maintained at 1 ml/min. The injection volume 
was 10 μl. The asenapine was analyzed using a PDA detector 
covering the range of 200–400 nm. 
The solvents and chemicals used in the preparation of the mobile 
phase were of HPLC grade and analytical grade, respectively. The 
mobile phase used was 0.1% orthophosphoric acid (Sd Fine 
Chemicals Ltd., Mumbai): methanol (Merck, Mumbai, India) in the 
ratio of 65:35 (v/v). The mobile phase was filtered through millipore 
filter before use and degassed for 15 min by sonication. 
Drug standard solutions 
The standard stock solution (1 mg/ml) was prepared by dissolving 
100 mg of asenapine in 100 ml mobile phase. Working standard 
solutions equivalent to 100, 150, 200, 250, and 300 μg/ml asenapine 
were prepared by appropriate dilution of the stock standard 
solution with the mobile phase.  
Tablet sample solution 
Twenty tablets were weighed and crushed to a fine powder. The 
powder equivalent of 100 mg of asenapine was taken in a 100 ml 
volumetric flask containing 20 ml of mobile phase, sonicated for 20 
min and made up to mark with the same diluent. The mixture was 
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filtered through 0.45 µm filter paper and the resultant solution was 
diluted properly with the mobile phase to get a final concentration 
of 200 μg/ml asenapine.  
Stress degradation study 
Stress degradation study was performed by subjecting the tablet 
powder to degradations such as acid, alkaline, oxidative, thermal 
and photolytic conditions to assess the interference of degradants. 
Acid, base, and oxidative degradations were performed by adding 10 
ml of 0.1 N hydrochloric acid, 10 ml of 0.1 N sodium hydroxide and 
10 ml of 30% peroxide solution, respectively to the sample and 
sonicated for 30 min. The acid degraded sample and base degraded 
sample are neutralized with 0.1 N sodium hydroxide and 0.1 N 
hydrochloric acid, respectively. Thermal degradation was performed 
by keeping the sample in petri dish and then placing them in an oven 
at 105 o
Analysis of asenapine in bulk 
C for 30 min. The photolytic study was carried out by placing 
the sample in petri dish and exposed to sunlight for 24 h. The 
degraded samples were diluted with mobile phase to get the 
concentration of 200 μg/ml asenapine and 10 μl aliquot of each 
degraded sample was injected into the HPLC system.  
Ten μl aliquot of each working standard solution prepared in the 
section “Drug standard solutions” was injected automatically on to 
the column. The chromatograms and peak areas were recorded. The 
calibration curve was constructed by plotting the peak area against 
the concentration of the drug (μg/ml). The regression equation was 
derived. The concentration of unknown was determined either from 
the calibration curve or from the regression equation derived. 
Analysis of asenapine in tablet dosage forms 
Ten μl aliquot of tablet sample solution prepared in the section 
“Tablet sample solution” was injected automatically on to the 
column. The chromatograms were recorded. The peak area was 
calculated. The nominal content of asenapine in tablet dosage form 
was calculated either from the calibration curve or from the 
regression equation derived. 
RESULTS AND DISCUSSION 
Optimization of experimental parameters 
Chromatographic parameters such as mobile phase composition, 
wavelength of detection and analytical column were optimized to 
achieve better efficiency of the chromatographic system. Three 
different analytical columns, BDS Y Persil C18 (250 x 4.6 mm, 5 µm), 
YMC C18 (250 x 4.6 mm, 5 µm) and Kromasil C8 (250 x 4.6 mm, 5 µm) 
were tested during method development. The parameters like tailing 
factor, retention time and plate count were taken into consideration. 
Based on the above said parameters BDS Y Persil C18 (250 x 4.6 mm, 5 
µm) column was finalized for the analysis. Different composition of 
mobile phases containing a mixture (v/v) of 0.1 M mono potassium 
phosphate, methanol and 0.1 % orthophosphoric acid was evaluated 
in order to obtain suitable composition of the mobile phase.  
 
 
Fig. 1: Chromatogram of asenapine 
 
Finally the mixture of 0.1 % orthophosphoric acid and methanol in 
the ratio of 65:35 (v/v) was selected as optimal as it produced well 
defined and well resolved peak of asenapine at a flow rate of 1 
ml/min and with column temperature of 30 o
Method validation [17] 
C. For the detection and 
quantification of asenapine, 227 nm was selected as the optimum 
wavelength. Under the optimized chromatographic conditions, the 
retention time for asenapine was found to be 6.781 min. A typical 
chromatogram is given in fig. 1. 
System suitability 
For system suitability testing, five replicates of asenapine (200 
μg/ml) standard solutions were injected. The retention time, peak 
area, plate count and tailing factor of each replicate was established. 
The results of system suitability in comparison with the required 
limits are shown in table 1. The results are found to be within the 
accepted limits. 
 
Table 1: System suitability 
Parameters  Value  Recommended limits 
Retention time 6.769 - 
Peak area 3315183 
(% RSD–0.5) 
RSD ≤1 
USP plate count 7832 >2000 
USP tailing factor 0.94 ≤ 2 
RSD-Relative standard deviation, USP-
 
United States Pharmacopeial 
Convention 
Linearity 
The developed method was tested for linearity by plotting peak 
area against concentration of asenapine working standard 
solutions. The plot of peak area vs the respective concentrations of 
asenapine were found to be linear in the concentration range of 
100-300 µg/ml.  
The results of linearity and regression equation for asenapine were 
given in fig. 2. The results show that an excellent correlation exists 
between peak area and asenapine concentration within the 
concentration range indicated above.  
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Fig. 2: Linearity curve and regression equation 
 
Limit of quantification and detection 
Limit of quantification (LOQ) and detection (LOD) of the developed 
method were predicted by the following formulae 
(a) LOQ = 10 σ/S 
(b) LOD = 3.3 σ/S 
Where σ = standard deviation of response; S = slope of the 
calibration curve. 
The LOD and LOQ for asenapine were found to be 2.4 μg/ml and 8.0 
μg/ml, respectively.  
Kalpana et al. 




The precision of the developed method was determined by the 
analysis of asenapine at a fixed concentration (200 μg/ml) by six 
replicate analyses. The precision was expressed as percent relative 
standard deviation (% RSD). The % RSD was found to be 0.27 %, 
indicating that the method is precise.  
Accuracy 
To study the accuracy of the developed method, recovery studies 
were conducted at three concentrations of 50 %, 100 %, and 150 % 
levels by standard addition method. The accuracy expressed as 
percentage recoveries was shown in table 2. The results indicated 
that the method is accurate. 
  
Table 2: Accuracy of the method 
Spiked Level Concentration of asenapine (µg/ml)  % Recovery % Mean  
added found 
50% 99.857 99.52 100 100 
50% 99.857 99.59 100 
50% 99.857 99.78 100 
100% 200.000 200.09 100 100 
100% 200.000 200.09 100 
100% 200.000 199.52 100 
150% 299.572 299.38 100 100 
150% 299.572 299.29 100 
150% 299.572 298.77 100 
 
 
Fig. 3: Chromatogram of asenapine (50 % level) 
 
 
Fig. 4: Chromatogram of asenapine (100 % level) 
 
Specificity 
The specificity of the developed method was assessed through stress 
degradation studies. The degradation study was carried out using 
the tablet powder containing asenapine. The chromatograms of the 
stress degraded samples are shown in fig. 6-10. The samples 
submitted to degradation conditions showed significant alteration in 
the peak areas. In acid (fig. 6) and base (fig. 7) degraded samples one 
peak, in hydrogen peroxide (fig. 8) and photolytic (fig. 9) 
degradation two peaks were observed in addition to the asenapine 
peak. Though the peak area was altered in dry heat degradation (fig. 
10) process, no additional peak was observed. This may be due to the 
low concentration of the degradant. In all the stress conditions, the 
degradants peaks were well resolved from asenapine peak. The 
degradation results of various stress conditions were shown in table 3. 
 
Fig. 5: Chromatogram of asenapine (150 % level) 
 
Table 3: Stress degradation studies 
Type of degradation  Peak area % Assay % Degradation  
Acid 3451167 94 6.0 
Base 3524024 96 4.0 
Peroxide 3491778 95 5.0 
Heat 3475952 95 5.0 
Sunlight 3486605 95 5.0 
Undegraded 3315183 100 0.0 
 
 
Fig. 6: Chromatogram of acid degraded sample 
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Fig. 7: Chromatogram of base degraded sample 
 
 
Fig. 8: Chromatogram of hydrogen peroxide degraded sample 
 
Robustness 
In order to confirm the robustness of the method, system suitability 
parameters were evaluated at different flow rate and different 
column temperature. Parameters such as retention time, tailing 
factor and plate count used to define robustness. The results 
demonstrated (table 4) that slight variations in method parameters 
had an insignificant outcome on the analysis. 
 
 
Fig. 9: Chromatogram of photo degraded sample 
 
 
Fig. 10: Chromatogram of dry heat degraded sample 
 
Table 4: Robustness of the method 
Investigated parameter Retention time Peak area Plate Count Tailing 
Flow 1 8.964 4457510 8804 0.95 
Flow 2 8.600 4678832 6767 0.91 
Temperature 1 6.805 3315625 7580 0.95 
Temperature 2 6.535 3285496 8386 0.95 
 
CONCLUSION 
A stability indicating high performance liquid chromatographic method 
has been developed for the quantification of asenapine. The developed 
method was validated as per the guidelines of the International 
conference on harmonization. The method validation data demonstrated 
that the developed method is sensitive, precise, accurate, specific and 
robust. The method was proved to be stability indicating by the 
resolution of the asenapine from its stress degradation products. The 
method was found to be accurate for the estimation of asenapine in the 
tablets. Common excipients present in the tablet did not interfere with 
the assay. Hence, the validated high performance liquid chromatographic 
method can be employed in the routine analysis for the quantification of 
asenapine in tablet formulation. 
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